Try a new search

Format these results:

Searched for:

in-biosketch:true

person:goldbi05

Total Results:

305


Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction

Noh, Hye-Lim; Okajima, Kazue; Molkentin, Jeffery D; Homma, Shunichi; Goldberg, Ira J
The most energy-requiring organ in the body, the cardiac muscle, relies primarily on lipoprotein-derived fatty acids. Prenatal loss of cardiac lipoprotein lipase (LPL) leads to hypertriglyceridemia, but no cardiac dysfunction, in young mice. Cardiac specific loss of LPL in 8-wk-old mice was produced by a 2-wk tamoxifen treatment of MerCreMer (MCM)/Lpl(flox/flox) mice. LPL gene deletion was confirmed by PCR analysis, and LPL mRNA expression was reduced by approximately 70%. One week after tamoxifen was completed, triglyceride was increased with LPL deletion, 162 +/- 53 vs. 91 +/- 21 mg/dl, P < 0.01. Tamoxifen treatment of Lpl(flox/flox) mice did not cause a significant increase in triglyceride levels. Four weeks after tamoxifen, MCM/Lpl(flox/flox) mice had triglyceride levels of 190 +/- 27 mg/dl, similar to those of mice with prenatal LPL deletion. One week after the tamoxifen, MCM/Lpl(flox/flox), but not Lpl(flox/flox), mice had decreases in carnitine palmitoyl transferase I mRNA (18%) and pyruvate dehydrogenase kinase 4 mRNA (38%). These changes in gene expression became more robust with time. Acute loss of LPL decreased ejection fraction and increased mRNA levels for atrial natriuretic factor. Our studies show that acute loss of LPL can be produced and leads to rapid alteration in gene expression and cardiac dysfunction.
PMID: 16684851
ISSN: 0193-1849
CID: 948992

Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis

Wu, Lan; Vikramadithyan, Reeba; Yu, Shuiqing; Pau, Clara; Hu, Yunying; Goldberg, Ira J; Dansky, Hayes M
The factors underlying cardiovascular risk in patients with diabetes have not been clearly elucidated. Efforts to study this in mice have been hindered because the usual atherogenic diets that contain fat and cholesterol also lead to obesity and insulin resistance. We compared plasma glucose, insulin, and atherosclerotic lesion formation in LDL receptor knockout (Ldlr(-/-)) mice fed diets with varying fat and cholesterol content that induced similar lipoprotein profiles. Ldlr(-/-) mice fed a high-fat diet developed obesity, mild hyperglycemia, hyperinsulinemia, and hypertriglyceridemia. Quantitative and qualitative assessments of atherosclerosis were unchanged in diabetic Ldlr(-/-) mice fed a high-fat diet compared with lean nondiabetic control mice after 20 weeks of diet. Although one group of mice fed diets for 40 weeks had larger lesions at the aortic root, this was associated with a more atherogenic lipoprotein profile. The presence of a human aldose reductase transgene had no effect on atherosclerosis in fat-fed Ldlr(-/-) mice with mild diabetes. Our data suggest that when lipoprotein profiles are similar, addition of fat to a cholesterol-rich diet does not increase atherosclerotic lesion formation in Ldlr(-/-) mice.
PMID: 16840797
ISSN: 0022-2275
CID: 949002

Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1

Park, So-Young; Cho, You-Ree; Kim, Hyo-Jeong; Hong, Eun-Gyoung; Higashimori, Takamasa; Lee, Sang Jun; Goldberg, Ira J; Shulman, Gerald I; Najjar, Sonia M; Kim, Jason K
Mice with liver-specific overexpression of dominant negative phosphorylation-defective S503A-CEACAM1 mutant (L-SACC1) developed chronic hyperinsulinemia resulting from blunted hepatic clearance of insulin, visceral obesity, and glucose intolerance. To determine the underlying mechanism of altered glucose homeostasis, a 2-h hyperinsulinemic euglycemic clamp was performed, and tissue-specific glucose and lipid metabolism was assessed in awake L-SACC1 and wild-type mice. Inactivation of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) caused insulin resistance in liver that was mostly due to increased expression of fatty acid synthase and lipid metabolism, resulting in elevated intrahepatic levels of triglyceride and long-chain acyl-CoAs. Whole body insulin resistance in the L-SACC1 mice was further attributed to defects in insulin-stimulated glucose uptake in skeletal muscle and adipose tissue. Insulin resistance in peripheral tissues was associated with significantly elevated intramuscular fat contents that may be secondary to increased whole body adiposity (assessed by (1)H-MRS) in the L-SACC1 mice. Overall, these results demonstrate that L-SACC1 is a mouse model in which chronic hyperinsulinemia acts as a cause, and not a consequence, of insulin resistance. Our findings further indicate the important role of CEACAM1 and hepatic insulin clearance in the pathogenesis of obesity and insulin resistance.
PMID: 16638824
ISSN: 0193-1849
CID: 949012

Diabetic vascular disease: an experimental objective

Goldberg, Ira J; Dansky, Hayes M
It is well known that humans with diabetes have more atherosclerosis and its complications. The causes of this relationship are, however, unclear. Although recent data show that improved glycemic control reduces arterial disease in type 1 diabetes, other studies have shown that subjects with "prediabetes" have more cardiovascular disease before the development of hyperglycemia. Thus, either hyperglycemia and/or lack of insulin actions are toxic to arteries, or metabolic derangements exclusive of hyperglycemia are atherogenic. For >50 years animal models of diabetes and atherosclerosis have been used to uncover potential mechanisms underlying diabetes associated cardiovascular disease. Surprisingly, diabetes alone increases vascular disease in only a few select animal models. Increased atherosclerosis has been found in several animals and lines of genetically modified mice; however, diabetes often also leads to greater hyperlipidemia. This makes it difficult to separate the toxic effects of insulin lack and/or hyperglycemia from those caused by the lipids. These studies are reviewed, as well as more recent investigations using new methods to create diabetic-atherosclerotic models.
PMID: 16763160
ISSN: 1079-5642
CID: 949022

Inhibition of pancreatic lipase by poloxamer 407 may provide an adjunct treatment strategy for weight loss

Johnston, Thomas P; Goldberg, Ira J
This investigation was conducted to evaluate whether poloxamer 407 (P-407), a nonionic surface-active-agent that functions as a lipase inhibitor, could aid in weight loss by inactivating pancreatic lipase (PL) following oral administration to mice. Using a pH-titrimetric method, P-407 was evaluated for its ability to inhibit PL activity in-vitro. The palatability of drinking water containing P-407 (50 microM) was assessed in mice to determine whether inclusion of P-407 altered either the volume of water ingested, or the volume of urine produced, per day. P-407 at the same concentration was next evaluated for its potential to mediate weight loss over a one-month period in mice fed a high-fat diet. Faecal fat determinations and the potential for P-407 to lower plasma triacylglycerol concentrations following oral administration of a standard lipid emulsion were also conducted. P-407 was determined to have an IC50 of 15.9 microM in-vitro. Inclusion of P-407 in drinking water neither perturbed the daily volume of water ingested, nor the volume of urine produced. Over the course of one month, adult mice, which were fed the high-fat diet and treated with P-407, lost approximately 12.4+/-1.7% of their initial body weight, whereas, control mice fed the identical diet continued to slowly gain weight (7.3+/-0.5% of their initial body weight). The amount of total lipids excreted in the faeces of high-fat-fed, P-407-treated mice was approximately 45% greater than that observed for control mice eating the same diet. Lastly, plasma triacylglycerol concentrations following oral administration of the standard lipid emulsion containing P-407 were significantly lower than corresponding plasma triacylglycerol concentrations observed in mice administered the lipid emulsion alone. While not as potent as orlistat, P-407 may potentially represent an additional treatment strategy for weight loss, especially when combined with caloric restriction, regular exercise, and anti-obesity medications of other drug classes.
PMID: 16872557
ISSN: 0022-3573
CID: 949032

Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease

Goldberg, Ira J; Ginsberg, Henry N
PMID: 16618425
ISSN: 0016-5085
CID: 949042

Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction

Augustus, Ayanna S; Buchanan, Jonathan; Park, Tae-Sik; Hirata, Kumiko; Noh, Hye-Lim; Sun, Jie; Homma, Shunichi; D'armiento, Jeanine; Abel, E Dale; Goldberg, Ira J
Long-chain fatty acids (FAs) are the predominant energy substrate utilized by the adult heart. The heart can utilize unesterified FA bound to albumin or FA obtained from lipolysis of lipoprotein-bound triglyceride (TG). We used heart-specific lipoprotein lipase knock-out mice (hLpL0) to test whether these two sources of FA are interchangeable and necessary for optimal heart function. Hearts unable to obtain FA from lipoprotein TG were able to compensate by increasing glucose uptake, glycolysis, and glucose oxidation. HLpL0 hearts had decreased expression of pyruvate dehydrogenase kinase 4 and increased cardiomyocyte expression of glucose transporter 4. Conversely, FA oxidation rates were reduced in isolated perfused hLpL0 hearts. Following abdominal aortic constriction expression levels of genes regulating FA and glucose metabolism were acutely up-regulated in control and hLpL0 mice, yet all hLpL0 mice died within 48 h of abdominal aortic constriction. Older hLpL0 mice developed cardiac dysfunction characterized by decreased fractional shortening and interstitial and perivascular fibrosis. HLpL0 hearts had increased expression of several genes associated with transforming growth factor-beta signaling. Thus, long term reduction of lipoprotein FA uptake is associated with impaired cardiac function despite a compensatory increase in glucose utilization.
PMID: 16410253
ISSN: 0021-9258
CID: 949052

Retinoid absorption and storage is impaired in mice lacking lecithin:retinol acyltransferase (LRAT)

O'Byrne, Sheila M; Wongsiriroj, Nuttaporn; Libien, Jenny; Vogel, Silke; Goldberg, Ira J; Baehr, Wolfgang; Palczewski, Krzysztof; Blaner, William S
Lecithin:retinol acyltransferase (LRAT) is believed to be the predominant if not the sole enzyme in the body responsible for the physiologic esterification of retinol. We have studied Lrat-deficient (Lrat-/-) mice to gain a better understanding of how these mice take up and store dietary retinoids and to determine whether other enzymes may be responsible for retinol esterification in the body. Although the Lrat-/- mice possess only trace amounts of retinyl esters in liver, lung, and kidney, they possess elevated (by 2-3-fold) concentrations of retinyl esters in adipose tissue compared with wild type mice. These adipose retinyl ester depots are mobilized in times of dietary retinoid insufficiency. We further observed an up-regulation (3-4-fold) in the level of cytosolic retinol-binding protein type III (CRBPIII) in adipose tissue of Lrat-/- mice. Examination by electron microscopy reveals a striking total absence of large lipid-containing droplets that normally store hepatic retinoid within the hepatic stellate cells of Lrat-/- mice. Despite the absence of significant retinyl ester stores and stellate cell lipid droplets, the livers of Lrat-/- mice upon histologic analysis appear normal and show no histological signs of liver fibrosis. Lrat-/- mice absorb dietary retinol primarily as free retinol in chylomicrons; however, retinyl esters are also present within the chylomicron fraction obtained from Lrat-/- mice. The fatty acyl composition of these (chylomicron) retinyl esters suggests that they are synthesized via an acyl-CoA-dependent process suggesting the existence of a physiologically significant acyl-CoA:retinol acyltransferase.
PMCID:1352312
PMID: 16115871
ISSN: 0021-9258
CID: 949062

Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice

Vikramadithyan, Reeba K; Hu, Yunying; Noh, Hye-Lim; Liang, Chien-Ping; Hallam, Kellie; Tall, Alan R; Ramasamy, Ravichandran; Goldberg, Ira J
Direct evidence that hyperglycemia, rather than concomitant increases in known risk factors, induces atherosclerosis is lacking. Most diabetic mice do not exhibit a higher degree of atherosclerosis unless the development of diabetes is associated with more severe hyperlipidemia. We hypothesized that normal mice were deficient in a gene that accelerated atherosclerosis with diabetes. The gene encoding aldose reductase (AR), an enzyme that mediates the generation of toxic products from glucose, is expressed at low levels in murine compared with human tissues. Mice in which diabetes was induced through streptozotocin (STZ) treatment, but not nondiabetic mice, expressing human AR (hAR) crossed with LDL receptor-deficient (Ldlr-/-) C57BL/6 male mice had increased aortic atherosclerosis. Diabetic hAR-expressing heterozygous LDL receptor-knockout mice (Ldlr+/-) fed a cholesterol/cholic acid-containing diet also had increased aortic lesion size. Lesion area at the aortic root was increased by STZ treatment alone but was further increased by hAR expression. Macrophages from hAR-transgenic mice expressed more scavenger receptors and had greater accumulation of modified lipoproteins than macrophages from nontransgenic mice. Expression of genes that regulate regeneration of glutathione was reduced in the hAR-expressing aortas. Thus, hAR increases atherosclerosis in diabetic mice. Inhibitors of AR or other enzymes that mediate glucose toxicity could be useful in the treatment of diabetic atherosclerosis
PMCID:1190371
PMID: 16127462
ISSN: 0021-9738
CID: 130836

Perfusion of hearts with triglyceride-rich particles reproduces the metabolic abnormalities in lipotoxic cardiomyopathy

Pillutla, Priya; Hwang, Yuying C; Augustus, Ayanna; Yokoyama, Masayoshi; Yagyu, Hiroaki; Johnston, Thomas P; Kaneko, Michiyo; Ramasamy, Ravichandran; Goldberg, Ira J
Hearts with overexpression of anchored lipoprotein lipase (LpL) by cardiomyocytes (hLpL(GPI) mice) develop a lipotoxic cardiomyopathy. To characterize cardiac fatty acid (FA) and triglyceride (TG) metabolism in these mice and to determine whether changes in lipid metabolism precede cardiac dysfunction, hearts from young mice were perfused in Langendorff mode with [14C]palmitate. In hLpL(GPI) hearts, FA uptake and oxidation were decreased by 59 and 82%, respectively. This suggests reliance on an alternative energy source, such as TG. Indeed, these hearts oxidized 88% more TG. Hearts from young hLpL(GPI) mice also had greater uptake of intravenously injected cholesteryl ester-labeled Intralipid and VLDL. To determine whether perfusion of normal hearts would mimic the metabolic alterations found in hLpL(GPI) mouse hearts, wild-type hearts were perfused with [14C]palmitate and either human VLDL or Intralipid (0.4 mM TG). Both sources of TG reduced [14C]palmitate uptake (48% with VLDL and 45% with Intralipid) and FA oxidation (71% with VLDL and 65% with Intralipid). Addition of either heparin or LpL inhibitor P407 to Intralipid-containing perfusate restored [14C]palmitate uptake and confirmed that Intralipid inhibition requires local LpL. Our data demonstrate that reduced FA uptake and oxidation occur before mechanical dysfunction in hLpL(GPI) lipotoxicity. This physiology is reproduced with perfusion of hearts with TG-containing particles. Together, the results demonstrate that cardiac uptake of TG-derived FA reduces utilization of albumin-FA
PMID: 15701679
ISSN: 0193-1849
CID: 130837